A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
260actual
Sites
115
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-23 | actual | When the study began enrolling |
| Primary completion | 2026-01-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-28 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumors
Intervention
- Drug: Bemarituzumab — also filed as AMG 552
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
measured Day 1 to Day 28
Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
measured Day 1 to 28 days after last dose (a maximum of 2 years)
Part 1: Number of Participants Who Experience a Treatment-related Adverse Event
measured Day 1 to 28 days after last dose (a maximum of 2 years)
Part 2: Objective Response (OR) Rate
measured Up to approximately 2 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed